| Title: |
Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. |
| Authors: |
Viktorin-Baier, Pascal; Putora, Paul M.; Schmid, Hans-Peter; Plasswilm, Ludwig; Schwab, Christoph; Thoeni, Armin; Hochreiter, Werner; Prikler, Ladislav; Suter, Stefan; Stucki, Patrick; Müntener, Michael; Blick, Nadja; Schiefer, Hans; Güsewell, Sabine; Zürn, Karin; Engeler, Daniel |
| Source: |
Viktorin-Baier, Pascal; Putora, Paul M.; Schmid, Hans-Peter; Plasswilm, Ludwig; Schwab, Christoph; Thoeni, Armin; Hochreiter, Werner; Prikler, Ladislav; Suter, Stefan; Stucki, Patrick; Müntener, Michael; Blick, Nadja; Schiefer, Hans; Güsewell, Sabine; Zürn, Karin; Engeler, Daniel (2020). Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU international, 125(6), pp. 827-835. Wiley 10.1111/bju.15003 |
| Publisher Information: |
Wiley |
| Publication Year: |
2020 |
| Collection: |
BORIS (Bern Open Repository and Information System, University of Bern) |
| Subject Terms: |
610 Medicine & health |
| Description: |
OBJECTIVE To evaluate the long-term oncological, functional and toxicity outcomes of low-dose-rate brachytherapy (LDR-BT) in relation to risk factors and radiation dose in a prospective multicentre cohort. PATIENTS AND METHODS Data of patients from 12 Swiss centres undergoing LDR-BT from September 2004 to March 2018 were prospectively collected. Patients with a follow-up of ≥3 months were analysed. Functional and oncological outcomes were assessed at ~6 weeks, 6 and 12 months after implantation and annually thereafter. LDR-BT was performed with 125 I seeds. Dosimetry was done 6 weeks after implantation based on the European Society for Radiotherapy and Oncology recommendations. The Kaplan-Meier method was used for biochemical recurrence-free survival (BRFS). A prostate-specific antigen (PSA) rise above the PSA nadir + 2 was defined as biochemical failure. Functional outcomes were assessed by urodynamic measurement parameters and questionnaires. RESULTS Of 1580 patients in the database, 1291 (81.7%) were evaluable for therapy outcome. The median (range) follow-up was 37.1 (3.0-141.6) months. Better BRFS was found for Gleason score ≤3+4 (P = 0.03, log-rank test) and initial PSA level of |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://boris.unibe.ch/147623/ |
| Availability: |
https://boris.unibe.ch/147623/1/bju.15003.pdf; https://boris.unibe.ch/147623/ |
| Rights: |
info:eu-repo/semantics/restrictedAccess |
| Accession Number: |
edsbas.2A33434F |
| Database: |
BASE |